Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479882 | 1.00 | NPSR1 (0.41) | NPSR1HCAR2HPGD | |
| SCHEMBL7562797 | 0.80 | FFAR3 (0.33) | — | |
| SCHEMBL7562791 | 0.80 | FFAR3 (0.33) | — | |
| SCHEMBL6472629 | 0.78 | NPSR1 (0.44) | NPSR1HCAR2HPGD | |
| SCHEMBL6472630 | 0.78 | NPSR1 (0.44) | NPSR1HCAR2HPGD | |
| SCHEMBL6472670 | 0.76 | NPSR1 (0.46) | NPSR1HCAR2 | |
| SCHEMBL6472672 | 0.76 | NPSR1 (0.46) | NPSR1HCAR2 | |
| SCHEMBL1244345 | 0.69 | ALDH1A1 (0.40) | NPSR1HCAR2 | |
| SCHEMBL11469721 | 0.69 | NPSR1 (0.54) | NPSR1HCAR2 | |
| SCHEMBL6472642 | 0.69 | SMN1; SMN2 (0.43) | NPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921777-B2 | Heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-26 | — | — | US | disclosed |
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-01-16 | — | — | US | disclosed |
| US-6444709-B1 | SKIN DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2002-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | TYR, CYP1B1, MITF | NPSR1 1200/4885HCAR2 238/4885HPGD 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.